Healthcare / Biotechnology
Exclusive insider sentiment analysis for the Biotechnology sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:30 | 2026-04-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer; Chief Financial Officer | Biotechnology | OPT+S | $105.21 | 11,430 | $1,202,526 | 85,533 | -11.8% |
| 2026-04-03 20:53 | 2026-04-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer; EVP and Chief Legal Officer | Biotechnology | SALE | $449.17 | 978 | $439,288 | 21,833 | -4.3% |
| 2026-04-03 20:10 | 2026-04-01 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer; Chief Financial Officer | Biotechnology | SALE | $18.64 | 5,727 | $106,751 | 125,373 | -4.4% |
| 2026-04-03 20:24 | 2026-04-01 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Officer; Chief Medical Officer | Biotechnology | SALE | $31.05 | 1,000 | $31,050 | 68,747 | -1.4% |
| 2026-04-03 20:12 | 2026-04-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer; CHIEF MEDICAL OFFICER | Biotechnology | SALE | $32.66 | 1,838 | $60,029 | 38,864 | -4.5% |
| 2026-04-03 20:01 | 2026-04-01 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | Biotechnology | SALE | $777.27 | 100 | $77,727 | 17,603 | -0.6% |
| 2026-04-03 21:00 | 2026-04-02 | CAPR | CAPRICOR THERAPEUTICS, INC. | Sabar Karimah Es | Director | Biotechnology | OPT+S | $32.00 | 7,529 | $240,928 | 0 | -100.0% |
| 2026-04-03 20:07 | 2026-04-01 | INSM | INSMED Inc | Adsett Roger | Officer; Chief Operating Officer | Biotechnology | OPT+S | $164.63 | 88,060 | $14,497,652 | 106,810 | -45.2% |
| 2026-04-04 01:29 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer; Chief Financial Officer | Biotechnology | OPT+S | $49.34 | 7,500 | $370,076 | 97,994 | -7.1% |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer; Chief Medical Officer | Biotechnology | OPT+S | $50.00 | 7,958 | $397,900 | 0 | -100.0% |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $49.33 | 15,000 | $739,913 | 627,540 | -2.3% |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer; Chief Financial Officer | Biotechnology | SALE | $85.01 | 2,000 | $170,020 | 177,371 | -1.1% |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer; Chief Medical Officer | Biotechnology | OPT+S | $84.84 | 5,500 | $466,619 | 208,398 | -2.6% |
| 2026-04-03 23:46 | 2026-04-02 | IMNM | Immunome Inc. | Rosett Max | Officer; Chief Financial Officer | Biotechnology | OPT+S | $21.92 | 65,000 | $1,424,917 | 54,037 | -54.6% |
| 2026-04-03 23:48 | 2026-04-02 | IMNM | Immunome Inc. | Higgins Jack | Officer; Chief Scientific Officer | Biotechnology | SALE | $21.64 | 9,438 | $204,238 | 22,000 | -30.0% |
| 2026-04-03 22:17 | 2026-04-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | Director, Officer; CHIEF EXECUTIVE OFFICER | Biotechnology | OPT+S | $3.48 | 26,858 | $93,466 | 793,549 | -3.3% |
| 2026-04-03 21:55 | 2026-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Director, Officer; President and CEO | Biotechnology | SALE | $3.87 | 11,511 | $44,548 | 472,549 | -2.4% |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer; See Remarks | Biotechnology | OPT+S | $20.39 | 9,910 | $202,065 | 59,761 | -14.2% |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer; Chief Financial Officer | Biotechnology | OPT+S | $20.39 | 5,199 | $106,008 | 32,558 | -13.8% |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer; Chairperson & CEO | Biotechnology | OPT+S | $20.39 | 5,576 | $113,695 | 1,125,279 | -0.5% |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer; Chief Legal Officer | Biotechnology | OPT+S | $20.39 | 4,194 | $85,516 | 24,590 | -14.6% |
| 2026-04-03 21:59 | 2026-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer; See Remarks | Biotechnology | OPT+S | $20.39 | 9,614 | $196,029 | 120,619 | -7.4% |
| 2026-04-03 21:45 | 2026-04-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer; See Remarks | Biotechnology | SALE | $5.99 | 16,667 | $99,859 | 1,209,840 | -1.4% |
| 2026-04-03 21:46 | 2026-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | Biotechnology | SALE | $23.88 | 10,000 | $238,801 | 39,744 | -20.1% |
| 2026-04-03 21:09 | 2026-04-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | Biotechnology | SALE | $190.50 | 6,000 | $1,143,010 | 384,682 | -1.5% |
| 2026-04-03 21:20 | 2026-04-01 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer; CHIEF TECHNICAL OPS OFFICER | Biotechnology | SALE | $69.04 | 52,003 | $3,590,240 | 60,137 | -46.4% |
| 2026-04-03 21:06 | 2026-04-02 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | Biotechnology | BUY | $2.10 | 713,800 | $1,498,980 | 3,288,539 | +27.7% |
| 2026-04-03 20:33 | 2026-04-02 | IMVT | Immunovant, Inc. | Venker Eric | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $24.10 | 14,229 | $342,855 | 19,561 | -42.1% |
| 2026-04-03 20:06 | 2026-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer; CHIEF OPERATING OFFICER | Biotechnology | SALE | $58.43 | 2,250 | $131,476 | 162,994 | -1.4% |
| 2026-04-03 19:13 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer; Chief Medical Officer | Biotechnology | OPT+S | $16.00 | 679 | $10,864 | 3,622 | -15.8% |
| 2026-04-03 19:14 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer; Chief Financial Officer | Biotechnology | SALE | $16.96 | 15,959 | $270,593 | 17,338 | -47.9% |
| 2026-04-03 15:23 | 2026-04-01 | NRXS | Neuraxis, INC | Henrichs Timothy Robert | Officer; Chief Financial Officer | Biotechnology | BUY | $1.96 | 7,593 | $14,882 | 7,593 | +100.0% |
| 2026-04-03 15:19 | 2026-04-01 | NRXS | Neuraxis, INC | Carrico Brian Allen | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $1.96 | 8,060 | $15,798 | 348,178 | +2.4% |
| 2026-04-03 15:21 | 2026-04-01 | NRXS | Neuraxis, INC | Carrico Thomas Joeseph | Officer; CRO, CCO, CPO | Biotechnology | BUY | $1.96 | 667 | $1,307 | 331,903 | +0.2% |
| 2026-04-03 13:00 | 2026-04-01 | ERAS | Erasca, Inc. | Garner Ebun | Officer; Chief Legal Officer | Biotechnology | OPT+S | $16.40 | 80,000 | $1,312,000 | 25,076 | -76.1% |
| 2026-04-03 11:29 | 2026-04-01 | CGEN | COMPUGEN LTD | Ophir Eran | Director, Officer; President and CEO | Biotechnology | OPT+S | $2.21 | 5,625 | $12,413 | 11,375 | -33.1% |
| 2026-04-03 11:31 | 2026-04-01 | CGEN | COMPUGEN LTD | Levine Zurit | Officer; SVP, Business Development | Biotechnology | OPT+S | $2.20 | 3,500 | $7,700 | 29,375 | -10.6% |
| 2026-04-02 20:06 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | Officer; SVP, Finance | Biotechnology | OPT+S | $29.44 | 2,500 | $73,611 | 12,965 | -16.2% |
| 2026-04-02 20:08 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer; President, R&D & CMO | Biotechnology | OPT+S | $29.46 | 15,000 | $441,905 | 0 | -100.0% |
| 2026-04-02 21:58 | 2026-04-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer; EVP & CFO | Biotechnology | SALE | $48.33 | 34,791 | $1,681,512 | 32,916 | -51.4% |
| 2026-04-02 20:47 | 2026-03-31 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | Officer; SVP, Chief Technical Officer | Biotechnology | SALE | $2.50 | 2,867 | $7,168 | 195,338 | -1.4% |
| 2026-04-02 20:39 | 2026-04-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer; Chief Financial Officer | Biotechnology | SALE | $12.95 | 2,500 | $32,375 | 119,010 | -2.1% |
| 2026-04-02 21:12 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Neal James R | Director | Biotechnology | BUY | $2.54 | 789 | $2,000 | 818 | +2,720.7% |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer; CHIEF EXECUTIVE OFFICER | Biotechnology | OPT+S | $30.93 | 60,000 | $1,855,842 | 432,886 | -12.2% |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer; Chief Legal Officer and GC | Biotechnology | OPT+S | $30.00 | 10,000 | $300,000 | 105,211 | -8.7% |
| 2026-04-03 01:00 | 2026-03-31 | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% owner | Biotechnology | SALE | $3.34 | 5,880,415 | $19,636,470 | 10,265,297 | -36.4% |
| 2026-04-03 00:26 | 2026-04-02 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer; Chief Financial Officer | Biotechnology | OPT+S | $39.92 | 30,000 | $1,197,489 | 183,316 | -14.1% |
| 2026-04-03 00:09 | 2026-04-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer; President, R&D | Biotechnology | OPT+S | $21.20 | 27,000 | $572,478 | 112,622 | -19.3% |
| 2026-04-02 23:43 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | Biotechnology | SALE | $202.23 | 467 | $94,440 | 42,253 | -1.1% |
| 2026-04-02 23:43 | 2026-04-02 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer; EVP, Chief Human Resources Ofc | Biotechnology | SALE | $74.05 | 6,193 | $458,613 | 16,348 | -27.5% |
Strategic Analysis
Analyzing insider transactions within the Biotechnology sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.